Lonza and China Medical System Holdings (CMS) have signed a global exclusive license agreement covering Lonza's NeuroPortal transferrin receptor 1 (TfR1) blood-brain barrier technology for up to two products targeting neurodegenerative diseases. CMS receives development and commercial rights for the agreed product targets, while Lonza retains the ability to license the platform for other therapeutic programs.
Under the agreement, Lonza will receive an upfront payment, development and commercial milestone payments, and royalties on net sales. The deal is the first license Lonza has granted for the newly acquired platform, which is designed to support delivery of biologics across the blood-brain barrier.
The barrier protects the brain but prevents many medicines from reaching it, creating a challenge for central nervous system drug development. NeuroPortal offers binding variants with different affinities, allowing developers to evaluate receptor engagement, transport across the barrier and brain exposure for individual therapeutic molecules.
Lonza said the technology outperformed an industry benchmark in preclinical studies when used as an IgG fusion and when combined with its GlycoConnect platform. Peter Droc, Lonza's head of licensing, said the platform allows developers to explore genetic fusion or bioconjugation approaches and tailor delivery strategies to their therapeutic molecules.
Detailed platform results are scheduled for presentation at the 18th annual Protein & Antibody Engineering Summit in Lisbon, Portugal, taking place November 16–19. Hong Kong-headquartered CMS develops and commercializes specialty medicines, including treatments for central nervous system disorders, alongside programs in cardiovascular-kidney-metabolic disease, gastroenterology, ophthalmology and skin health, using both internal and collaborative research and development approaches.